Teresa Vitali

Teresa Vitale of Scotiabank inquired about commercial strategies to encourage physicians to switch patients from luspatercept to RYTELO sooner, and asked about the reasons for any KOL hesitation to prescribe RYTELO in earlier lines of therapy.

Answer

Jim Ziegler, Chief Commercial Officer, noted that market research shows physician awareness of RYTELO's profile drives favorable perceptions and that recent data shows 20% of use is now in first and second lines. Dr. Joseph Eid, EVP of R&D, added that data presented at ASH demonstrated imetelstat's efficacy post-luspatercept and that physician hesitancy often stems from a lack of awareness, which is overcome with education on the drug's unique mechanism.

Teresa Vitali, on for Greg Harrison, asked how Alnylam is leveraging its commercial expertise and what specific strategies are being employed to capture patients switching from tafamidis.

Answer

Chief Commercial Officer Tolga Tanguler explained that AMVUTTRA's distinct mechanism of action and compelling HELIOS-B data, where nearly half of patients were already on a stabilizer, position it as a clear first-line option. He added that for patients progressing on stabilizers, AMVUTTRA is a very important treatment option, and the company is already seeing uptake in this switch population.